Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis
Year: 2017
Type: article
Abstract: Recently, we reported a novel role for KMO in the pathogenesis of acute pancreatitis (AP). A number of inhibitors of kynurenine 3-monooxygenase (KMO) have previously been described as potential treatments for neurodegenerative conditions and particularly for Huntington's disease. However, the inhibitors reported to date have insufficient aqueous solubility relative to their cellular potency to be compatible with the intravenous (iv) dosing route required in AP. We have identified and optimized a novel series of high affinity KMO inhibitors with favorable physicochemical properties. The leading example is exquisitely selective, has low clearance in two species, prevents lung and kidney damage in a rat model of acute pancreatitis, and is progressing into preclinical development.
Source: Journal of Medicinal Chemistry
Authors: Ann L. Walker, Nicolas Ancellin, Benjamin Beaufils, Marylise Bergeal, Margaret Binnie, Anne Bouillot, David Clapham, Alexis Denis, Carl P. Haslam, Duncan S. Holmes, Jonathan P. Hutchinson, John Liddle, Andrew McBride, Olivier Mirguet, Christopher G. Mowat, Paul Rowland, Nathalie Tiberghien, Lionel Trottet, Iain Uings, Scott P. Webster, Xiaozhong Zheng, Damian J. Mole
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2601428988